Wall Street Zen downgraded shares of Grace Therapeutics (NASDAQ:GRCE – Free Report) from a sell rating to a strong sell rating in a research report sent to investors on Saturday.
Several other equities analysts have also recently weighed in on GRCE. Zacks Research raised shares of Grace Therapeutics to a “hold” rating in a research note on Monday, August 3rd. TD Cowen dropped their price target on shares of Grace Therapeutics from $12.00 to $8.00 and set a “buy” rating on the stock in a research report on Friday, April 24th. Craig Hallum set a $4.00 price target on shares of Grace Therapeutics in a research report on Friday, April 24th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Grace Therapeutics in a research note on Friday, July 17th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $6.00.
Check Out Our Latest Research Report on Grace Therapeutics
Grace Therapeutics Stock Performance
Grace Therapeutics (NASDAQ:GRCE – Get Free Report) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.91) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.78). During the same period in the previous year, the business earned ($0.21) earnings per share. As a group, research analysts forecast that Grace Therapeutics will post -0.8 EPS for the current year.
Institutional Trading of Grace Therapeutics
Institutional investors and hedge funds have recently bought and sold shares of the business. SeaCrest Wealth Management LLC acquired a new stake in shares of Grace Therapeutics in the third quarter valued at approximately $42,000. Kestra Private Wealth Services LLC acquired a new position in shares of Grace Therapeutics during the 1st quarter worth approximately $60,000. BlackRock Inc. bought a new stake in Grace Therapeutics in the 2nd quarter valued at $85,000. XTX Topco Ltd bought a new stake in Grace Therapeutics in the 4th quarter valued at $106,000. Finally, Pale Fire Capital SE bought a new stake in Grace Therapeutics in the 1st quarter valued at $175,000. Institutional investors own 6.08% of the company’s stock.
About Grace Therapeutics
Grace Therapeutics, Inc (NASDAQ: GRCE) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for rare genetic diseases. By employing a proprietary platform that integrates advanced molecular biology and biologic engineering, the company focuses on identifying and optimizing gene-based and protein-based candidates designed to address well-defined genetic drivers of disease.
The company’s pipeline features multiple preclinical programs targeting lysosomal storage disorders and other inherited metabolic conditions.
Featured Articles
- Five stocks we like better than Grace Therapeutics
- Is Best Buy the AI Winner Hiding in the Electronics Aisle?
- Applied Materials Beat Everything but Wall Street’s Expectations for Margins
- Back From Orbit, Intuitive Machines’ Share Price Enters the Buy Zone
- Texas Roadhouse and Brinker International Have the Recipe Rivals Are Missing
Receive News & Ratings for Grace Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grace Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
